CSF AND PLASMA-CONCENTRATIONS OF MORPHINE AND MORPHINE GLUCURONIDES IN CANCER-PATIENTS RECEIVING EPIDURAL MORPHINE

被引:38
作者
SAMUELSSON, H
HEDNER, T
VENN, R
MICHALKIEWICZ, A
机构
[1] GOTHENBURG UNIV,SAHLGRENS HOSP,S-41345 GOTHENBURG,SWEDEN
[2] PAIN RES INST,LIVERPOOL,ENGLAND
关键词
PAIN; CANCER; MORPHINE; MORPHINE METABOLITES; M3G; M6G;
D O I
10.1016/0304-3959(93)90129-D
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Thirty-five cancer patients, treated with chronic epidural morphine, were assayed for plasma and cerebrospinal fluid (CSF) minimum steady-state concentrations (Css min) of morphine (M), morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G) by high performance liquid chromatography (HPLC). A linear dose-concentration relationship was found for the 3 substances in plasma and for morphine and M3G in CSF. The mean +/- S.E.M. CSF/plasma morphine ratio was 158 +/- 43. In CSF, the concentrations of morphine exceeded those of the metabolites substantially and, normalized to morphine, the mean CSF M/M3G/M6G ratio was 1 : 0.05:0.02. In plasma, the metabolite concentrations were higher than the parent drug and the plasma M/M3G/M6G ratio was 1:12:3. The mean M3G and M6G concentrations in CSF were 40-60% of those found in plasma. Indication of cerebral formation of M3G was found in 1 patient. Pain relief, evaluated by a visual analogue scale (VAS), did not correlate with the CSF M3G concentrations or with the M3G/M ratio. CSF M6G concentrations were low and did not contribute to any detectable analgesia. We conclude that after epidural administration of morphine, the M3G and M6G metabolites in CSF are low compared to unchanged morphine and seem to have little influence on analgesia. Howewer, the fact that a significant passage of the glucuronide metabolites occurs to the CSF may indicate a role in morphine analgesia after other routes of administration.
引用
收藏
页码:179 / 185
页数:7
相关论文
共 29 条
[1]   MORPHINE-6-GLUCURONIDE - ANALGESIC EFFECTS AND RECEPTOR-BINDING PROFILE IN RATS [J].
ABBOTT, FV ;
PALMOUR, RM .
LIFE SCIENCES, 1988, 43 (21) :1685-1695
[2]   MORPHINE, MORPHINE-6-GLUCURONIDE AND MORPHINE-3-GLUCURONIDE CONCENTRATIONS IN PLASMA AND CEREBROSPINAL-FLUID DURING LONG-TERM HIGH-DOSE INTRATHECAL MORPHINE ADMINISTRATION [J].
BIGLER, D ;
CHRISTENSEN, CB ;
ERIKSEN, J ;
JENSEN, NH .
PAIN, 1990, 41 (01) :15-18
[3]   METABOLISM OF MORPHINE AND HEROIN IN MAN [J].
BOERNER, U ;
ABBOTT, S ;
ROE, RL .
DRUG METABOLISM REVIEWS, 1975, 4 (01) :39-73
[4]   MORPHINE 6-GLUCURONIDE AND MORPHINE 3-GLUCURONIDE AS MOLECULAR CHAMELEONS WITH UNEXPECTED LIPOPHILICITY [J].
CARRUPT, PA ;
TESTA, B ;
BECHALANY, A ;
ELTAYAR, N ;
DESCAS, P ;
PERRISSOUD, D .
JOURNAL OF MEDICINAL CHEMISTRY, 1991, 34 (04) :1272-1275
[5]   ANTINOCICEPTIVE AND VENTILATORY EFFECTS OF THE MORPHINE METABOLITES - MORPHINE-6-GLUCURONIDE AND MORPHINE-3-GLUCURONIDE [J].
GONG, QL ;
HEDNER, T ;
HEDNER, J ;
BJORKMAN, R ;
NORDBERG, G .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1991, 193 (01) :47-56
[6]  
GONG QL, 1992, PAIN, V48, P249, DOI 10.1016/0304-3959(92)90065-J
[7]   ANALGESIC EFFICACY AND CSF PHARMACOKINETICS OF INTRATHECAL MORPHINE-6-GLUCURONIDE - COMPARISON WITH MORPHINE [J].
HANNA, MH ;
PEAT, SJ ;
WOODHAM, M ;
KNIBB, A ;
FUNG, C .
BRITISH JOURNAL OF ANAESTHESIA, 1990, 64 (05) :547-550
[8]  
JOEL SP, 1985, LANCET, V1, P1099
[9]   MORPHINE DERIVATIVES WITH DIMINISHED OPIATE RECEPTOR POTENCY SHOW ENHANCED CENTRAL EXCITATORY ACTIVITY [J].
LABELLA, FS ;
PINSKY, C ;
HAVLICEK, V .
BRAIN RESEARCH, 1979, 174 (02) :263-271
[10]   METABOLISM OF NARCOTICS [J].
MCQUAY, H ;
MOORE, A .
BMJ-BRITISH MEDICAL JOURNAL, 1984, 288 (6412) :237-237